Plain-English translation of NCT07662759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new eye drop medication called to see if it can help lower the pressure inside your eyes and treat glaucoma or ocular hypertension. You would use the medication twice daily (morning and evening), and researchers will compare how well it works compared to other standard treatments. The goal is to understand whether this medication is safe and effective for patients like you.
Many people with glaucoma don't reach their target eye pressure with current treatments alone, which puts them at risk for vision loss. This trial is testing whether this medication could help patients who need better eye pressure control or are already using multiple medications.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of three treatment options, all given as eye drops twice daily (around 8:30 AM and 8:30 PM). Some participants will receive the new medication alone, while others will receive combinations of the new medication with other treatments. Throughout the study, you'll have regular visits where your eye pressure will be measured, your vision will be checked, and you'll be monitored for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
South Korea
Phase
Large-scale testing
Sponsor
Kukje Pharma
Enrollment target
~188 participants
Started
December 2025
Primary completion
March 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kukje Pharma Kukje Pharma
Kukje Pharma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.